Meeting
2018 ASCO Annual Meeting
A phase II study of study of bevacizumab (BEV) in combination with atezolizumab (ATEZO) in pts (pts) with untreated melanoma brain metastases (BEAT-MBM).
Authors
Gustavo Schvartsman
The University of Texas MD Anderson Cancer Center, Houston, TX
Gustavo Schvartsman , Isabella Claudia Glitza , Denai Milton , Rodabe Navroze Amaria , Patrick Hwu , Wen-Jen Hwu , Adi Diab , Michael K.K. Wong , Sapna Pradyuman Patel , Jeffrey Scott Wefel , Elizabeth M. Burton , Courtney Brown , Scott Eric Woodman , Ingrid M. Beosch , Caroline Chung , Michael A. Davies , Hussein Abdul-Hassan Tawbi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03175432
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS9598)
DOI
10.1200/JCO.2018.36.15_suppl.TPS9598
Abstract #
TPS9598
Poster Bd #
423b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2023 ASCO Annual Meeting
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
First Author: Aaron Scott Mansfield
Poster
2022 ASCO Annual Meeting
Phase 2 randomized trial of neoadjuvant or palliative chemotherapy with or without immunotherapy for peritoneal mesothelioma (Alliance A092001).
First Author: Aaron Scott Mansfield
Poster
2021 ASCO Annual Meeting
Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.
First Author: Max Jameson-Lee